Search for: [Abstract = "Objective\: In the thesis presented the evaluation of systemic production of PGD2 and leukoriene E4 \(LTE4\) was undertaken in stable and exacerbated COPD patients. Methods\: 29 COPD patients aged 73 ± 8,34, mean FEV1= 48,64 ± 15,75% of predictive value and 29 healthy controls aged 57,48 ± 10,86, mean FEV1= 97,17 ± 13,81% of predictive value participated in this study. Samples of urine and blood were taken from COPD patients during exacerbation and in stable state of the disease. LTE4 was determined in urine using commercial enzyme immunoassay \(EIA\) and 9ɑ11βPGF2 – stable metabolite of PGD2 was evaluated in blood and urine using gas chromatography\/mass spectrometry. The concentration of tryptase and C\- reactive protein were determined in blood at the same time. Results\: LTE4 concentration in urine and 9ɑ11βPGF2 in blood were significantly higher in exacerbated COPD patients than in healthy controls. There was no difference in LTE4 level in urine and 9ɑ11βPGF2 in blood between exacerbated and stable COPD. The urinary 9ɑ11βPGF2 concentration did not differ between all studied groups. In contrary, the CRP concentration was significantly higher in exacerbation of COPD compared to the stable state of the disease and control group. The tryptase level was lower during COPD exacerbation than in the control group and in stable patients. We found a positive correlation between smoking history and urine LTE4 as well as blood 9ɑ11βPGF2 concentrations in COPD patients. No correlation was observed between systemic eicosanoides production and severity of the disease as well as severity of exacerbation."]

Number of results: 0